Date: 2017-01-09
Type of information: Production agreement
Compound: ex-vivo autologous gene therapy products.
Company: Orchard Therapeutics (UK) PharmaCell (The Netherlands)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: production
Action mechanism: gene therapy
Disease:
Details:
- • On January 9, 2017, Orchard Therapeutics announced an alliance with PharmaCell, a leading contract manufacturing organization for cell and gene therapies and regenerative medicine. Under the terms of the alliance, PharmaCell will provide GMP-compliant manufacturing services to support clinical trials and commercialization of Orchard’s ex-vivo autologous gene therapy products.
- Orchard’s clinical development pipeline includes novel treatments for primary immune deficiency disorders and inherited metabolic disorders, including ADA-SCID (adenosine deaminase deficiency severe combined immunodeficiency) and MPS-IIIA (Mucopolysaccharidosis IIIA or Sanfilippo syndrome type A) as well as other indications.
Financial terms:
Latest news:
Is general: Yes
